Clinical Trial

A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight

Study acronym: SURPASS-T1D-2
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The main purpose of this study is to find out how well and how safely tirzepatide works long-term in adults who have type 1 diabetes and obesity or overweight. Participation in the study will last about 20 months.
Protocol Amendment History 16 amendments
This ClinicalTrials.gov record has been amended 16 times since 2025-05-06; most recent amendment 2026-02-13.
Status change: Recruiting → Active, Not Recruiting 2026-02-13
Status change: Not Yet Recruiting → Recruiting 2025-05-23
Trial Details
NCT Number NCT06962280
Lead Sponsor Eli Lilly and Company
Conditions Type 1 Diabetes, Obesity, Overweight
Enrollment 465 participants
Start Date 2025-05-12
Primary Completion 2026-11 (estimated)
Study Completion 2027-07 (estimated)
Updated on ClinicalTrials.gov 2026-02-17